Roche Pharmaceutical Development and Sales Overview
Pharma Division sales YTD Sep 2022
Product sales Pharmaceuticals Division
Roche
Global
US
Europe
Japan
International
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM
% CER
Ocrevus
Perjeta
4,427
17
3,283
13
808
25
336
37
3,090
5
1,135
1
661
-16
175
-1
1,119
33
Hemlibra
2,778
28
1,684
22
542
32
277
20
Tecentriq
2,692
10
1,451
9
573
19
326
-5
Actemra/RoActemra
2,039
-23
914
-33
602
-3
256
1
Herceptin
1,672
-18
376
-28
329
-13
40
-28
927
Avastin
1,652
-29
497
-36
158
-51
378
-15
Xolair
1,625
10
1,625
10
MabThera
1,596
-20
1,002
Kadcyla
1,590
11
619
Alecensa
1,127
16
TNKase / Activase
881
-8
Lucentis
800
-25
Evrysdi
793
101
Ronapreve
631
-36
Esbriet
590
-25
381
Gazyva
539
8
251
Phesgo
526
150
217
Pulmozyme
414
-1
280
CellCept
386
-12
Polivy
290
79
121
Vabysmo
282
Erivedge
200
2
Enspryng
133
108
Rozlytrek
53
50
Cotellic
35
1
Gavreto
20
299
Xofluza
6
Susvimo
3
WNG32ARENGE 822
-25
112
126
232922222232208
156
-18
24
-10
-3
508
101
218
6
169
-9
24
253
335
102
-81
452
52'' 26
21
5
409
60
42
-34
186
-1
144
-7
39
ā
263
204
73
-12
-19
101
-6
74
84
41
4
182
43
68
161
24
-6
44
7
*
135
6
86
87
40
9
83
5
22
11
-9
22222222222222622-8451
76
16
-39
-15
-21
-23
100
77
-49
23
-14
17
111
30
456
174
5
12 GON,
26
5
-22
89
-2
35
13
34
Lunsumio
1
1
Other Products
2,318
-15
538
-20
259
-20
506
-10
1,015
-13
Pharma Division
33,189
0
17,199
-1
6,100
-1
3,029
7
6,861
0
CER = Constant Exchange Rates (avg. full year 2021); *over 500%
147View entire presentation